Health and Fitness Health and Fitness
Tue, June 22, 2010
Mon, June 21, 2010
Sun, June 20, 2010
Fri, June 18, 2010
Thu, June 17, 2010
Wed, June 16, 2010
Tue, June 15, 2010
Mon, June 14, 2010
Sat, June 12, 2010
Fri, June 11, 2010
Thu, June 10, 2010
Wed, June 9, 2010
Tue, June 8, 2010
[ Tue, Jun 08th 2010 ] - Market Wire
O.C. Beverages Products Arrive
Mon, June 7, 2010
Sun, June 6, 2010
Sat, June 5, 2010
Fri, June 4, 2010

Curis Announces Change to Presentation Time at ThinkEquitya?s Mid Year Check-up on Healthcare Conference


//health-fitness.news-articles.net/content/2010/ .. -mid-year-check-up-on-healthcare-conference.html
Published in Health and Fitness on Monday, June 14th 2010 at 7:45 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its presentation time for the upcoming ThinkEquity Mid Year Check-up on Healthcare Conference has been changed to 10:00 a.m. EDT on June 16, 2010, in New York City.

Dan Passeri, Curisa™ President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor. GDC-0449 is currently being developed in three Phase II clinical trials by Curisa™ collaborator Genentech, including in a pivotal Phase II trial in advanced basal cell carcinoma and Phase II trials in metastatic colorectal cancer and advanced ovarian cancer. Mr. Passeri will also discuss CUDC-101, Debio 0932 and Curis' other targeted cancer programs, in addition to other corporate activities.

There will be a corresponding webcast of the presentation, which can be accessed by visiting: [ http://www.wsw.com/webcast/tep18/cris/ ]

The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at [ www.curis.com ].

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at [ www.curis.com ].


Publication Contributing Sources